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Edited by Varda RotterAbstract Expression of androgen receptor (AR) in prostate epi-
thelial cells is thought to regulate cell proliferation, diﬀerentia-
tion, and survival. However, the molecular mechanisms remain
unclear. We report that re-expression of AR in PC-3 human
prostate cancer cell line resulted in upregulation of IFI16 pro-
tein, a negative regulator of cell growth. We found that the
IFI16 protein bound to AR in a ligand-dependent manner and
the DNA-binding domain (DBD) of the AR was suﬃcient to bind
IFI16. Furthermore, re-expression of IFI16 protein in LNCaP
prostate cancer cells, which do not express IFI16 protein, re-
sulted in downregulation of AR expression and an inhibition of
the expression of AR target genes. Our observations identify a
role for IFI16 protein in AR-mediated functions.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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IFI161. Introduction
Studies using animal and cell model systems have indicated
that the expression of androgen receptor (AR) in prostate epi-
thelial cells regulates cell proliferation, diﬀerentiation, and sur-
vival [1–3]. Furthermore, embryonic prostate epithelial cells
from Rb-null mice were shown to express increased levels of
the AR protein [4], indicating that the Rb protein negatively
regulates the expression of AR. Importantly, mutations in
both Rb [5] and AR [3,6] genes have been reported during
the development of human prostate cancers.
Androgens activate the transcription of a set of interferon
(IFN)-activatable genes in cultured rat ventral prostate epithe-
lial cells [7]. Moreover, our recent study has revealed that treat-
ment of normal human prostate stromal or epithelial cells with
interferons (a, b, and c) results in increases in AR protein
levels and stimulation of AR-mediated transcription of AR-
responsive reporter genes [8]. Interestingly, the IFN-activatable
RNaseL protein binds to AR in a ligand-dependent manner and
the expression of activated AR renders cells insensitive to the
IFN treatment [9]. These studies suggest cross-talks between
androgen signaling and IFN signaling in prostate epithelial
and stromal cells. However, androgen and interferon eﬀector*Corresponding author. Fax: +1 708 202 2647.
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doi:10.1016/j.febslet.2006.02.015proteins that mediate the growth-regulatory functions in
prostate cells remain to be identiﬁed.
One family of interferon (IFN)-activatable genes is the 200-
gene family [10]. The family includes mouse (for example,
Iﬁ202a, Iﬁ202b, Iﬁ203, and Iﬁ204) and human genes (for
example, IFI16, MNDA, and AIM2) that encode structurally
related proteins (the p200-family proteins) [10,11]. Increased
expression of p200-family proteins, such as p202 [11,12] and
IFI16 [13,14], is known to inhibit cell cycle progression and
modulate apoptosis [15]. Moreover, the p200-family proteins
function as scaﬀold proteins and their binding to transcrip-
tion factors is known to modulate the transcription of genes.
Consistent with a role for IFI16 protein as a scaﬀold protein,
IFI16 protein binds to p53 [16], pRb [13], E2F1 [13], and
BRCA1 [15]. Furthermore, binding of IFI16 to Rb and
E2F1 is correlated with inhibition of E2F1-mediated tran-
scription [13].
Treatment of a variety of cells with IFNs (a, b, or c) has
been shown to result in upregulation of IFI16 mRNA and pro-
tein [10,13,14]. Interestingly, immortalization of normal hu-
man ﬁbroblasts with SV40 large T antigen, which is known
to inactivate both Rb and p53 tumor suppressors, resulted in
downregulation of IFI16 expression [14], raising the possibility
that the Rb and/or p53 pathways positively regulate the
expression of IFI16. Consistent with a role of IFI16 protein
in the Rb and p53 cell growth suppression pathways, the in-
creased expression of IFI16 protein in cultured normal human
ﬁbroblasts [14] and prostate epithelial cells [13] was associated
with cellular senescence. Moreover, knockdown of IFI16
expression in human diploid ﬁbroblasts inhibited p53-medi-
ated transcription, downregulated p21CIP1 expression, and ex-
tended the proliferation potential of cells [14]. Consistent with
a potential role for IFI16 in cellular senescence-associated cell
cycle arrest, the expression of IFI16 protein was either very
low or it was not detected in immortalized human ﬁbroblast
cell lines [14] and most prostate cancer cell lines tested [13]. Sig-
niﬁcantly, forced expression of IFI16 in prostate cancer cell
lines (LNCaP, PC-3, and DU-145) inhibits cell proliferation
[13], which in PC-3 cell line was associated with upregulation
of p21CIP1 expression and a senescence-like phenotype [13].
However, it remains unknown how the expression of IFI16
is regulated in prostate epithelial cells.
Here, we report that re-expression of AR in PC-3 cells re-
sulted in upregulation of IFI16 mRNA and protein. We also
found that increased expression of IFI16 in LNCaP prostate
cancer cells resulted in downregulation of AR expression and
an inhibition of AR-mediated transcription of target genes.blished by Elsevier B.V. All rights reserved.
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2.1. Cell culture and transfections
PC-3 and LNCaP prostate cancer cell lines were maintained in
DMEM culture medium (Invitrogen Life Technologies) supplemented
with 10% (v/v) fetal bovine serum and antibiotics. If so indicated, cells
were either cultured in basal medium (without phenol red; Cambrex,
Walkersville, MD) or RPMI 1640 (without phenol red; Invitrogen)
supplemented with 10% charcoal-stripped fetal bovine serum (CS-
FBS; Sigma). When indicated cells were cultured in the presence of
the indicated concentration of androgen receptor ligand dihydrotestos-
terone (DHT). PC-3 cells were transfected with an empty vector
(pCMV) or plasmid encoding human AR (pCMV-hAR; plasmid gen-
erously provided by Dr. N. Weigel, Baylor College of Medicine, Hous-
ton, TX). The transfected cells were selected in 500 lg/ml of G418 for
about two weeks and >100 G418-resistant colonies were pooled for
further analysis.
HEK-293 or LNCaP cells were nucleofected with pCMV-hAR,
pCDNA3-IFI16B, or an empty vector (pCMV) plasmid using Nucleo-
fector-II device (Amaxa Biosystems, Germany). HEK-293 and LNCaP
cells were nucleofected as suggested by the supplier using nucleofection
kit VCA-1003 (program Q-001) and VCA-1001 (program T-009),
respectively. If so indicated, 24–48 h after nucleofections of cells, cells
were grown in RPMI 1640 medium (without phenol red; Invitrogen)
supplemented with 10% CS-FBS and DHT (10 nM).
2.2. RT-PCR
Total RNA was isolated from the indicated cells using TRIzol re-
agent (Invitrogen) as suggested by the supplier. Isolated total RNA
was ﬁrst treated with DNase to eliminate contamination of any chro-
mosomal DNA. The treated RNA (0.5–1 lg) was subjected to One-
Step RT-PCR, using a pair of primer speciﬁc to IFI16 [14], and a kit
from Invitrogen Life Technologies, as suggested by the supplier.
2.3. Immunoblotting
Total cell lysates were subjected to immunoblotting as described pre-
viously [13]. Monoclonal mouse antibodies to IFI16 (sc-8023) and AR
(sc-7305) were purchased from Santa Cruz Biotech. Inc.
2.4. Immunoprecipitations and GST-pull-down assays
Immunoprecipitations using a monoclonal antibody (sc-8023; Santa
Cruz) to IFI16 protein, using a monoclonal (sc-7305; Santa Cruz) or a
polyclonal antibody to AR (sc-815) were performed as described pre-
viously [17]. Plasmids encoding GST-hAR (1–562), GST-hAR (544–
634), and GST-hAR (624–919) were generously provided by Dr. F.S.
French (University of North Carolina, Chapel Hill, NC). Plasmid
encoding GST-IFI16 has been described [13]. GST-fusion proteins
were produced, puriﬁed, and used as described previously [18].
2.5. Reporter assays
Dr. Alexander Chlenski (Northwestern University, Chicago) gener-
ously provided the pGL-AR3.5-luc (indicated as AR3.5-luc) reporter
plasmid [19]. We have ampliﬁed 1.68 kb genomic fragment from the
5 0-regulatory region of the IFI16-gene from a human genomic DNA
library (purchased from Clontech, Palo Alto, CA). We have sequenced
this 1.68 kb genomic fragment, identiﬁed a potential transcription ini-
tiation site, and analyzed for potential DNA binding sites for various
transcription factors. Moreover, we have linked this 1.68 kb regulatory
region of IFI16 to the luciferase reporter gene in pGL3 basic plasmid
(without any promoter and enhancer sequences), resulting in IFI16-
luc-reporter plasmid. The activity of IFI16-luc-reporter was stimulated
>2-fold in PC-3 and DU-145 cells by IFN-a or IFN-c treatment for
24 h. Luciferase reporter assays were performed as described previ-
ously [14].3. Results
We have reported previously that the expression of IFI16
mRNA and protein is either not detectable or very low in most
prostate cancer cell lines tested [13]. Additionally, we foundthat immortalization of normal human diploid ﬁbroblasts with
SV40 large T antigen, which inactivates both retinoblastoma
protein and p53 tumor suppressor [20], results in reduced
expression of IFI16 [14]. Because LNCaP prostate cancer cells
do not express detectable levels of IFI16 mRNA and protein
[13], to investigate whether AR could regulate the expression
of IFI16 in human prostate cancer cells, we chose the approach
involving re-expression of AR in PC-3 human prostate cancer
cell line.
3.1. Re-expression of AR in PC-3 cells activates the
transcription of the IFI16 gene
We have noted that PC-3 prostate cancer cells express
detectable levels of IFI16 mRNA and protein [13]. However,
these cells are reported to lack the expression of androgen
receptor [6]. Therefore, to determine whether androgens
through AR could regulate the expression of IFI16 in PC-3
prostate cancer cells, we generated a stable cell line (designated
as PC-AR) from a large pool of cell clones selected after trans-
fection of the plasmid (pCMV-AR) that allow the constitutive
expression of human androgen receptor. As a control, we also
generated a cell line from a large pool of vector (pCMV)-trans-
fected cells (designated as PC-V). As shown in Fig. 1A, PC-AR
cells expressed detectable levels of AR protein as compared to
PC-V cells (compare lane 4 with 2) and addition of androgen
receptor ligand DHT (1 nM) in the culture medium resulted
in further increases in AR protein levels (compare lane 3 with
4). Importantly, treatment of the PC-AR cells with increasing
concentrations of DHT for 24 h (Fig. 1B) or a ﬁxed concentra-
tion of DHT (10 nM) for the indicated duration of time
(Fig. 1C) resulted in increases in IFI16 protein levels. More-
over, we noted that the incubation of PC-AR cells with
DHT (1 nM) for 24 h resulted in accumulation (30–50%) of
AR protein in the nucleus (data not shown). Signiﬁcantly, lev-
els of IFI16 mRNA were measurably higher in PC-AR than
PC-V cells (Fig. 1D). Furthermore, a comparison of the activ-
ity of IFI16-luc-reporter between the PC-V and PC-AR cells
indicated that the activity of the reporter was about 2.5-fold
higher in the PC-AR than PC-V cells (Fig. 1E). Together, these
observations indicated that re-expression of AR in PC-3 cells
resulted in transcriptional activation of the IFI16 gene.
3.2. IFI16 protein associates with AR
Increased expression of the p200-family proteins and their
demonstrated binding to a number of transcription factors is
known to modulate the transcription of their target genes
[11,12]. Therefore, we explored whether IFI16 protein could
bind to AR. As shown in Fig. 2A, AR was detected in immu-
noprecipitates using a monoclonal antibody to IFI16 protein
in immunoprecipitation-immunoblotting assays (IP-IB assays)
from extracts derived from HEK-293 cells (we chose these cells
because they do not express detectable levels of AR, however,
they express low basal levels of IFI16 protein; data not shown)
that were transfected with plasmids encoding AR and IFI16,
but not AR or IFI16 alone. Furthermore, treatment of
HEK-293 cells with androgen-ligand DHT resulted in measur-
able increases in association between IFI16 and AR protein in
IP-IB assays (Fig. 2B), indicating that interactions between
IFI16 and AR may depend on the AR ligand DHT.
LNCaP cells express a mutant form (T877A) of the AR pro-
tein [3,6], but do not express IFI16 protein [13]. Therefore, to
Fig. 1. Re-expression of AR protein in PC-3 cells results in upregulation of IFI16 expression. (A) Extracts prepared from vector (PC-V; lanes 1 and
2) or AR (PC-AR; lanes 3 and 4) transfected cells, either left untreated (lanes 2 and 4) or treated with DHT (1 nM for 24 h; lanes 1 and 3) were
analyzed by immunoblotting using antibodies speciﬁc to the indicated proteins. (B) Extracts prepared from PC-AR cells cultured (for 24 h) in
medium supplemented with 10% CS-FBS (lane 1) or 10% CS-FBS and the indicated concentration of DHT were analyzed by immunoblotting using
antibodies speciﬁc to the indicated protein. (C) Extracts prepared from PC-AR cells cultured in medium supplemented with 10% CS-FBS and 10 nM
DHT for the indicated time (h) were analyzed by immunoblotting using antibodies speciﬁc to the indicated protein. (D) Total RNA isolated from
PC-V (lane 1) or PC-AR (lane 2) cells (cultured as described in panel C) was subjected to semi-quantitative RT-PCR using a pair of primer speciﬁc to
the indicated gene. (E) Sub-conﬂuent PC-V or PC-AR cells were transiently transfected with IFI16-luc-reporter plasmid as described in Section 2.
The normalized relative activity of the IFI16-luc-reporter is shown.
Fig. 2. IFI16 protein binds to AR. (A) Sub-conﬂuent cultures of HEK-293 cells were nucleofected with equal amounts of an empty plasmid (pCMV;
lane 1), plasmid pCDNA3-IFI16B encoding the IFI16 protein (lanes 3 and 4), or plasmid pCMV-AR encoding the AR protein (lanes 2 and 4). 24 h
after nucleofections, cell lysates were subjected to immunoprecipitations using monoclonal antibody to IFI16 protein. Total cell lysates as well as the
immunoprecipitates were analyzed by immunoblotting using antibodies speciﬁc to the indicated proteins. (B) Sub-conﬂuent cultures of HEK-293
cells were nucleofected with equal amounts of pCDNA3-IFI16B plasmid encoding IFI16 protein (lanes 2 and 4), or pCMV-AR plasmid encoding AR
protein (lanes 1–4). 24 h after nucleofections, cell were incubated with medium supplemented with CS-FBS or CS-FBS and 10 nMDHT for 24 h. Cell
lysates were subjected to immunoprecipitations using antibodies to IFI16 protein. Total cell lysates as well as the immunoprecipitates were analyzed
by immunoblotting using antibodies to the indicated proteins. (C) Sub-conﬂuent cultures of LNCaP cells were nucleofected with equal amounts of
pCDNA3 plasmid (vector; lane 1) or pCDNA3-IFI16B plasmid encoding IFI16 protein (lanes 2). 24 h after nucleofections, cell lysates were subjected
to immunoprecipitations using monoclonal antibody to IFI16 protein. Total cell lysates as well as the immunoprecipitates were analyzed by
immunoblotting using antibodies to the indicated proteins. (D) Sub-conﬂuent cultures of LNCaP cells were nucleofected with equal amounts of
pCDNA3 plasmid (vector; lane 1) or pCDNA3-IFI16B plasmid encoding IFI16 protein (lanes 2). 24 h after nucleofections, cell lysates were subjected
to immunoprecipitations using either a mouse monoclonal (MM) or a rabbit polyclonal (RP) antibody to the AR protein. Total cell lysates (left
panel) as well as the immunoprecipitates (right panel) were analyzed by immunoblotting using antibodies to the indicated proteins.
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in vivo, we restored the expression of IFI16 protein in LNCaP
cells and performed IP-IB assays. As shown in Fig. 2C, ARprotein was detected in IFI16 immunoprecipitates from ex-
tracts derived from LNCaP cells (cells grown in medium sup-
plemented with 10 nM DHT) that were transfected with a
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(compare lane 2 with 1). Conversely, IFI16 protein was de-
tected in AR immunoprecipitates using the C-terminal rabbit
polyclonal antibody (RP) to AR, but not a monoclonal anti-
body (MM) against the epitope comprising amino acids 299–
315 (Fig. 2D, compare lane 5 with 3), from extracts derived
from LNCaP cells that were transfected with a plasmid encod-
ing IFI16 protein, but not an empty vector (Fig. 2D, right pa-
nel, compare lane 5 with 4). Together, these observations
indicated that IFI16 protein associated with the endogenous
mutant (T877A) AR protein in extracts derived from the
LNCaP cells.
Association of IFI16 protein with AR in above experiments
prompted us to localize IFI16 binding region(s) in AR protein.
Therefore, we performed GST-pull-down assays in which we
incubated extracts from PC-3 (these cells express detectable
levels of IFI16 protein; Fig. 1) with glutathione–sepharose
beads (Fig. 3A, lane 2) or beads loaded with the indicated
GST-AR proteins. As shown in Fig. 3A and B, IFI16 in ex-
tracts derived from the PC-3 cells bound to AR in highly con-
served DNA-binding domain (amino acids 544–634) and not
in the N-terminal (amino acids 1–562) or the C-terminal (ami-
no acids 624–919) region. Together, these observations indi-
cated that IFI16 protein associated with AR in vitro and
in vivo and a conserved DNA-binding domain (DBD) in AR
is suﬃcient to bind IFI16 protein in vitro.
3.3. Re-expression of IFI16 in LNCaP cells downregulates the
AR expression and inhibits AR-mediated transcription
Binding of IFI16 protein to AR in DNA-binding region in
above experiments prompted us to test whether re-expression
of IFI16 in LNCaP cells, which do not express IFI16 protein
[13], has any eﬀect on AR-mediated transcription. For this
purpose, we nucleofected the LNCaP cells with increasing
amounts of the pCDNA3-IFI16B plasmid that encodes theFig. 3. IFI16 binds to AR in the DNA binding domain. (A) Extracts from P
with the indicated GST-AR-fusion proteins. Bound cellular proteins were
fraction (2%) of total cell extracts was also run in lane 1. (B) Schematic presen
IFI16 protein in assays shown in Fig. 1A–E.IFI16B protein or, as a negative control, an empty pCDNA3
plasmid, and analyzed the expression levels of IFI16, AR,
and prostate speciﬁc antigen (PSA; a transcriptional target of
the AR) mRNA levels by RT-PCR. As shown in Fig. 4A,
re-expression of IFI16 in LNCaP cells resulted in measurable
decreases in the levels of the AR mRNA and moderate de-
creases in PSA mRNA levels. Moreover, we noted that re-
expression of IFI16B in LNCaP cells also resulted in decreases
in AR protein levels (Fig. 4B) and 40–50% decrease in the
activity of AR3.5-luc-reporter, the expression of which was
driven by the 3.5-kb 5 0-regulatory region of the AR gene
[19]. Because increased expression of IFI16 protein in prostate
cancer cell lines (including the LNCaP) inhibits cell prolifera-
tion [13], we compared the expression of AR target protein,
the PSA and other growth-regulatory proteins between vector
and IFI16 nucleofected LNCaP cells. As shown in Fig. 4C, re-
expression of IFI16 protein in LNCaP cells resulted in appre-
ciable decreases in levels of AR, PSA, Cyclin A, and Cyclin D1
protein levels. Interestingly, we noted an increase in p73, a
member of the p53 protein family, protein levels and moderate
decreases in E2F1 protein levels. Together, these observations
suggested that re-expression of IFI16 in LNCaP cells inhibits
cell proliferation, in part, by downregulating the expression
of AR and by inhibiting the AR-mediated transcription of
its target genes.4. Discussion
The p200-family proteins are thought to function as scaﬀold
proteins that assemble protein complexes regulating transcrip-
tion of genes [13,14]. Therefore, the function of IFI16 protein
in cell growth regulation depends on its ability to bind with
other proteins and modulate their functions. To date, several
cellular proteins have been known to bind IFI16 protein.C-3 cells were incubated with sepharose beads (lane 2) or beads loaded
analyzed by immunoblotting using monoclonal antibody to IFI16. A
tation of various structural domains of human AR and their binding to
Fig. 4. Re-expression of IFI16 protein in LNCAP cells downregulates the expression of AR. (A) Sub-conﬂuent cultures of LNCaP cells were
nucleofected with pCDNA3 plasmid (vector; lane 1) or increasing amounts of pCDNA3-IFI16B plasmid. 24 h after nucleofections, total RNA was
isolated from attached and ﬂoating cells. Equal amounts of total RNA was subjected to RT-PCR using a pair of primers speciﬁc to IFI16, human
AR, PSA, or actin gene. (B) LNCaP cells were nucleofected as described in panel A, and 24 h after nucleofections total cell lysates were analyzed by
immunoblotting using antibodies speciﬁc to the indicated proteins. (C) LNCaP cells were transiently transfected with AR3.5-luc-reporter and pRL-
TK-reporter plasmids (in 5:1 ratio) along with the indicated expression plasmid using Superfect transfection agent (Qiagen). The amount of total
transfected plasmid DNA was adjusted to 2 lg using an empty pCDNA3 plasmid. 45 h after transfections, the ﬁreﬂy luciferase and Renilla luciferase
activities were determined. The normalized relative luciferase activity is shown. (D) Sub-conﬂuent cultures of LNCaP cells were nucleofected with
pCDNA3 (lane 1) or pCDNA3-IFI16B (lane 2) plasmid. 24 h after nucleofections, total cell lysates were analyzed by immunoblotting using
antibodies speciﬁc to the indicated proteins.
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[16]. Importantly, cell growth inhibition by IFI16, in part, de-
pends on its ability to potentiate the Rb/E2F-mediated tran-
scriptional repression [13] and to upregulate the expression
of p21CIP1 in p53-dependent [14] and independent manner [13].
Genetic alterations in the p16/Rb pathway are required for
bypassing cellular senescence in human prostate epithelial cells
[21]. Our observations that: (i) re-expression of AR in PC-3
cells results in upregulation of IFI16 (Fig. 1); (ii) IFI16 protein
binds to AR in DNA-binding region (Fig. 3); and (iii) re-
expression of IFI16 protein in LNCaP cells results in downreg-
ulation of AR expression and inhibition of the expression of
AR target proteins (Fig. 4), provide support for the idea that
the upregulation IFI16 by AR in prostate epithelial cells is a
part of an important negative feedback loop, which regulates
the expression of AR and AR-mediated functions.
Increased AR mRNA levels have been detected in senescent
normal human prostate epithelial cells [22]. Because IFI16 lev-
els also increase in senescent normal human prostate epithelial
cells [13], further work is in progress to determine whether the
AR-mediated upregulation of IFI16 in prostate epithelial cells
contributes to senescence-associated cell growth arrest.
Re-expression of AR in PC-3 cells was found to inhibit cell
proliferation [23,24]. Consistent with these reports, we also
noted that re-expression of AR in PC-3 cells (PC-AR cells;
Fig. 1) resulted in retardation of cell proliferation as compared
to vector transfected cells (data not shown). Because increasedexpression of IFI16 protein in PC-3 cells inhibits cell prolifer-
ation [13], our observations provide support for the idea that
AR-mediated upregulation of IFI16 in PC-3 cells contributes
to inhibition of cell growth.
Mutations in p53 gene are thought to be a late event during
the development of prostate cancer [1] and loss of p53 function
in prostate epithelial cells is known to confer a hormone resis-
tance phenotype [25]. Because IFI16 binds to p53 and potenti-
ates the p53-mediated transcription [14,16], our observations
raise the possibility that reduced expression of IFI16 in pros-
tate cancer cells may also contribute to hormone resistant phe-
notype. Consistent with this idea, downregulation of p21CIP1
expression in prostate cancer cells is linked to androgen inde-
pendence [26].
We have noted that the 1.6 kb 5 0-regulatory region of the
IFI16 gene, which we have analyzed for the presence of poten-
tial AR binding sites, does not contain the well-known (5 0-
GGA/TACANNNTGTTCT-3 0) AR-responsive elements
(AREs). However, it does contain several 6-bp-long (5 0-
TGTTCT-3 0) ARE’s core sequences that are ﬂanked by the
AP-1 DNA binding sites. Because the AR can activate the
transcription of genes through binding to the transcription fac-
tor c-Jun [27], and AP-1 (c-Jun and c-Fos) is known to activate
the transcription of IFI16 gene [28], additional work will be
needed to determine whether AR could activate the transcrip-
tion of IFI16 gene in prostate epithelial cells through the c-Jun/
AP-1 DNA-binding sites.
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the hormone-binding domain and regulate its transcriptional
activity [29]. We have noted that IFI16 protein contains at
least ﬁve LXXLL-like motifs (7NxxLL11, 25VXXLL29,
33LXXNL37, 62LXXLI66, and 75LXXLA79; the numbers indi-
cate the amino acid residues in IFI16 protein) in the N-termi-
nus. Additionally, the IFI16 protein contains two partially
conserved repeats of 200-amino acid residues (also called
HIN-200 domain), which are found in all p200-family proteins
and are shown to participate in protein–protein interactions
[11,12]. Because IFI16 protein bound to AR in DNA-binding
domain in GST-pull-down assays (Fig. 3) and not in the hor-
mone binding domain, further work is in progress to identify
the AR binding region(s) in the IFI16 protein.
In summary, our observations provide evidence for the
role of IFI16 in AR-mediated regulation of prostate epithe-
lial cell growth. These observations will serve as basis to:
(i) elucidate the molecular mechanisms by which IFI16 con-
tributes to the regulation of prostate epithelial cell growth;
(ii) determine how loss of IFI16 expression in normal pros-
tate epithelial cells contributes to the initiation and progres-
sion of prostate cancer through deregulation of AR
expression.
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